Partnered summer 2017 with Sanofi on 2 of our 7 programs developing new insulin molecules to improve outcomes in $25 --> 70B insulin market.
- Stage Prototype Ready
- Industry Biotechnology
- Location Newton, MA, USA
- Currency USD
- Founded January 2017
- Employees 23
- Incorporation Type C-corp
- Website thermalin.com
Thermalin is developing next-generation insulins to fill gaps in a rapidly growing $25B market. Our new molecules include ultra-concentrated, ultra-rapid-acting/fast offset meal-time and pump insulin ($7B addressable), ultra-heat stable, long- and biphasic ($8B+) insulin, glucose responsive insulins, and dermal patch insulin. Thermalin has partnered two of these programs with Sanofi and will be seeking partners for the other programs.
Bruce FrankVP Insulin Development
Bruce was co-inventor of Humalog and retired from Eli Lilly after 34-years in which he held several senior management positions in insulin discovery, development, manufacturing, and regulatory affairs. He received his Ph.D. in Physical Biochemistry from Northwestern and did his post-doc at Berkley.
Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.
Michael WeissFounder & Chief Innovation Officer
Expert on insulin analog design; currently Chairman, Biochemistry & Molecular Biology, Indiana University School of Medicine, >150 publications on insulin, 4 “Paper of the Week” in JBC. Former Chair of Biochemistry and Chair of NIDDK’s Board of Scientific Councilors. MD, summa cum laude & PhD in biophysics from Harvard.
CEO, Healthcare Capital, LLC; former CEO of Joslin Diabetes Center in Boston; founder of Prism Ventures; John serves on several life science and not-for-profit boards.
Thomas HattierVP of R & D
Thom is an accomplished researcher, who has driven development efforts in the biotech and biopharma sectors, including at Myriad Genetics, AmpliCon, and Cellular Technology. Thom earned a BA at Connecticut College; an MS in biochemistry, PhD in pathology, and completed post-doctoral work in molecular genetics, all at Case Western Reserve University.
Michael BarronAttorneyUnconfirmedStephen DiPalma,Unconfirmed
Massachusetts Medical AngelsUnconfirmedSanofi SunriseUnconfirmed